Mohammad Ali Shafa; Hosseinali Ebrahimi; Farhad Iranmanesh; Mojtaba Sasaie
Volume 15, Issue 4 , October 2016, , Pages 209-213
Abstract
Background: Diabetes is a well-known risk factor for acute ischemic stroke (AIS). Some recent studies point to hemoglobin A1c (HbA1c) may have prognostic value in nondiabetic and diabetic patients with ischemic stroke (IS). The aim of this study was to evaluate the prognostic value of HbA1c on mortality ...
Read More
Background: Diabetes is a well-known risk factor for acute ischemic stroke (AIS). Some recent studies point to hemoglobin A1c (HbA1c) may have prognostic value in nondiabetic and diabetic patients with ischemic stroke (IS). The aim of this study was to evaluate the prognostic value of HbA1c on mortality and morbidity in AIS patients with and without diabetic.Methods: In this prospective observational study, 150 diabetic and nondiabetic patients with AIS were evaluated for serum HbA1c level, hypertension (HTN), hyperlipidemia, and smoking in the first 24 hours of admission to determine their value to predict mortality and mortality at 30 and 90 days. Morbidity was estimated by the National Institutes of Health Stroke Scale (NIHSS) and follow-up visits were scheduled 30 and 90 days after admission. Results were analyzed with independent t-test and logistic regression analysis.Results: In this study, 73 patients (48.7%) were female and the rest were men. At 30 days, the diabetic patients had a significantly higher mortality, but no significant difference was found between diabetics and morbidity. No significant statistical differences were seen between HbA1c and 30 and 90 days with mortality and morbidity among diabetic patients. Furthermore, no significant statistical difference was seen between HbA1c and 30 and 90 days morbidity and between HbA1c and 30 days mortality in nondiabetic patients. However, in nondiabetic patients, on multiple logistic regression analysis, a significant correlation was seen between 90 days month mortality and HbA1c (P = 0.002).Conclusion: HbA1c can be as a predictive biomarker in nondiabetic patients with AIS.
